

HF Glossary and References

Glossary

AA(s), African American(s)	HR, heart rate
ACC(F)/AHA, American College of Cardiology (Foundation)/American Heart Association	hrs, hours
ACEI, angiotensin-converting enzyme inhibitor	HTN, hypertension
ADHF, acute decompensated heart failure	Hx, history
ADLs, activities of daily life	HYD/ISDN, hydralazine/isosorbide dinitrate
ARB, angiotensin receptor blocker	Int, intermediate
ARNI, angiotensin receptor-neprilysin inhibitor	K+, potassium
ASCVD, atherosclerotic cardiovascular disease	LDL-C, low-density lipoprotein cholesterol
b/c, because	LFTs, liver function tests
BID, twice per day (bis in die, Latin)	LVEF, left ventricular ejection fraction
BMI, body mass index	MACE, major adverse cardiovascular events
BNP, brain natriuretic peptide	MI, myocardial infarction
BP, blood pressure	MPI, myocardial perfusion imaging
bpm, beats per minute	Na+, sodium
BUN, blood urea nitrogen	NP, natriuretic peptide
CBC, complete blood count	NPs, nurse practitioners
CKD, chronic kidney disease	NT-proBNP, N-terminal-proB-type natriuretic peptide
Cl ⁻ : chloride	NYHA, New York Heart Association
CO ₂ , carbon dioxide	PBO, placebo
combo, combination	PCP, primary care provider
CVD, cardiovascular disease	PLT, platelet
DPP-4, dipeptidyl peptidase 4	pt(s), patient(s)
Dx, diagnose(d)	QD, once per day (quaque die, Latin)
dys, dysfunction	QOL, quality of life
Dz, disease	R/O, rule out
ECDP, Expert Consensus Decision Pathway	RBC, red blood cell
ECG, electrocardiogram	rehab, rehabilitation
EF, ejection fraction	RPhs, pharmacists
eGFR, estimated glomerular filtration rate	RR, relative reduction
ESC, European Society of Cardiology	RRR, regular rate and rhythm
ESRD, end-stage renal disease	sCR, serum creatinine
FPG, fasting plasma glucose	SGLT2, sodium glucose co-transporter 2
GDMT, guideline-directed medical therapy	SOC, standard of care
HbA _{1c} , glycated hemoglobin A _{1c}	Sxs, symptoms
HBP, high blood pressure	T2DM, type 2 diabetes mellitus
HCP, healthcare provider	TSH, thyroid stimulating hormone
Hct, hematocrit	TTE, transthoracic echocardiogram
HD, heart disease	Tx, treatment
HDL-C, high-density lipoprotein cholesterol	TZDs, thiazolidinediones
HF, heart failure	UACR, urine albumin-to-creatinine ratio
HFmEF, heart failure with mid-range ejection fraction	w/o, without
HFpEF, heart failure with preserved ejection fraction	WBC, white blood cell
HFREF, heart failure with reduced ejection fraction	wks, weeks
Hgb, hemoglobin	yrs, years
HHS, Department of Health and Human Services	
hosp, hospitalization(s)	

HF Glossary and References

References

American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care*. 2018;41(Suppl 1):S13–S27.

Benjamin EJ, Muntner P, Bittencourt AA, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation*. 2019;139:e56–e528.

Carnethon MR, Howard G, Albert MA, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. *Circulation*. 2017;136:e393–e423.

Department of Health and Human Services (HHS). Million Hearts. Health and Human Services website. <https://millionhearts.hhs.gov/>. Accessed November 19, 2019.

Entresto® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.

Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. *Circulation*. 2019;139:1384–1395.

Goff DC Jr., Lloyd-Jones DM, Coady BG, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49–S73.

Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2009;53:e1–e90.

Invokana® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993–1004.

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019 Sep 19. [Epub ahead of print]

Pereira ANP, Aras R, Macedo CRB, et al. Angiotensin-converting enzyme inhibitor-induced cough prevalence in refractory hypertensive patients. *J Hypertens Manag*. 2016;2:015.

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380:2295–2306.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association of the ESC. *Eur J Heart Fail*. 2016;18:891–975.

Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med*. 2004;351:2049–2057.

Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med*. 2019;380:539–548.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71:e127–e248.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. *J Am Coll Cardiol*. 2013;62:e147–e239.

Yancy CW, Januzzi JL Jr., Butler AL, et al. 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol*. 2018;71:201–230.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. *J Am Coll Cardiol*. 2017;70:776–803.